Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference  held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is “Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)”. This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue. Hemispherx BioPharma, Inc (NYSEMKT:HEB) stock performance was -5.70% in last session and finished the day at $0.440. Traded volume was 8.39million shares in the last session and the average volume of the stock remained 3.28million shares. The beta of the stock remained 1.78. Hemispherx BioPharma, Inc (NYSEMKT:HEB) insider ownership is 2.27%.

Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) phase I dose-escalation clinical trial of Supinoxin (RX-5902) in cancer patients with solid tumors is expected to be completed in the fourth quarter of 2014. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) dropped -0.77 percent to $1.29 Monday on volume of 6.75million shares. The intra-day range of the stock was $1.18 to $1.33. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has a market capitalization of $60.27million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. The company said its fourth quarter revenues totaled $6.5 million, including $2.4 million in BELVIQ product revenue, of which $2.3 million represented 31.5% of Eisai’s net product sales and $0.1 million related to redemptions of the 15-day free trial voucher. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on Mar 24, 2014 reported a decrease of -2.11% to the closing price of $6.02. Its fifty two weeks range is $4.05 -$9.25. The total market capitalization recorded $1.32billion. The overall volume in the last trading session was 5.91million shares. In its share capital, HEB has 218.65million outstanding shares.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) has begun a trial to study a treatment for the most common form of lung cancer, and while the drug works the same way as the biotech firm’s first approved drug, Iclusig, the company doesn’t expect it to show similar side effects. On Monday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) dropped -3.06% to close the day at $7.60. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -14.32%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is 37.68%.